S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ARQT Arcutis Biotherapeutics Inc

9.26

-0.67 (-6.75%)

16 Nov 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/02/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Todd Watanabe

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Arcutis Biotherapeutics Charts.

Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Arcutis Biotherapeutics Charts.

Arcutis Biotherapeutics Inc News

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
Thursday 14 November 2024 (4 days ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
Thursday 7 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 5 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 5 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Saturday 2 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
Thursday 24 October 2024 (3 weeks ago) • GlobeNewswire Inc.

More Arcutis Biotherapeutics Inc News Articles

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions